100% accuracy
of data
of data
24/7 scientific
support
support
0% tolerance in
quality of product
quality of product
Stock Locations
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* Stock subject to availability.
Documentation
Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.
Dapagliflozin Bromo Impurity
● In Stock
| Catalogue No.: | VE0011402 |
|---|---|
| CAS No.: | N/A |
| Mol. Formula: | C23H27BrO7 |
| Mol. Weight: | 495.37 g/mol |
Order Online
Additional information on Dapagliflozin Bromo Impurity
Parent drug
DapagliflozinIUPAC Name
(2S,3R,4R,5S,6R)-2-(4-bromo-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triolSynonyms
Dapagliflozin Bromo Impurity Dapagliflozin Bromo Compound 4-Bromo-1 chloro-2-[(4-ethoxyphenyl)methyl]benzene 4-(5-Bromo-2 chlorobenzyl)phenyl ethyl ether 5-Bromo-2-chloro-4′ ethoxydiphenylmethaneDescription
Dapagliflozin Bromo Impurity is a halogenated process-related impurity associated with the dapagliflozin scaffold, most plausibly arising from bromination during synthesis or from residual aryl bromide intermediates. Its molecular formula, C23H27BrO7, and molecular weight, 495.37 g/mol, indicate a brominated O-glycoside with physicochemical properties distinct from the parent API, including altered polarity and mass spectral isotopic pattern. Structural assignment and trace quantification generally require LC-MS/MS or high-resolution MS, often complemented by NMR and HPLC with photodiode array detection. Although not a nitrosamine, it falls within impurity profiling expectations under modern regulatory control strategies.Request a Quote
"*" indicates required fields
Other products related to Dapagliflozin impurities
Impurity structure
Parent Drug Name
CAS No.
Name of Impurity
Catalog No.
Dapagliflozin
CAS No. N/A
Cat No. VE009529